A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort pMDI [budesonide/formoterol] 40/2.25 microg twice daily compared with 1 inhalation Symbicort Turbuhaler [budesonide/formoterol] 80/4.5 microg twice daily and 1 inhalation Pulmicort Turbuhaler [budesonide] 100 microg twice daily.

Trial Profile

A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort pMDI [budesonide/formoterol] 40/2.25 microg twice daily compared with 1 inhalation Symbicort Turbuhaler [budesonide/formoterol] 80/4.5 microg twice daily and 1 inhalation Pulmicort Turbuhaler [budesonide] 100 microg twice daily.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2014

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ESTHER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Aug 2012 Actual end date changed from 1 Feb 2008 to 1 Apr 2008 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual end date (1 Feb 2008) added as reported by EudraCT.
    • 15 Apr 2008 Status change from in progress to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top